WO2005067931A3 - Dopamine uptake inhibitors for the treatment of neurological disease - Google Patents

Dopamine uptake inhibitors for the treatment of neurological disease Download PDF

Info

Publication number
WO2005067931A3
WO2005067931A3 PCT/GB2005/000119 GB2005000119W WO2005067931A3 WO 2005067931 A3 WO2005067931 A3 WO 2005067931A3 GB 2005000119 W GB2005000119 W GB 2005000119W WO 2005067931 A3 WO2005067931 A3 WO 2005067931A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
uptake inhibitors
dopamine uptake
neurological disease
convulsions
Prior art date
Application number
PCT/GB2005/000119
Other languages
French (fr)
Other versions
WO2005067931A2 (en
Inventor
Paul Goldsmith
Frances Margaret Richards
Derek Thomas Edward Jones
Ann Gail Hayes
Original Assignee
Daniolabs Ltd
Paul Goldsmith
Frances Margaret Richards
Derek Thomas Edward Jones
Ann Gail Hayes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniolabs Ltd, Paul Goldsmith, Frances Margaret Richards, Derek Thomas Edward Jones, Ann Gail Hayes filed Critical Daniolabs Ltd
Publication of WO2005067931A2 publication Critical patent/WO2005067931A2/en
Publication of WO2005067931A3 publication Critical patent/WO2005067931A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Treatment of diseases and disorders related to altered neuronal excitability, especially migraine prophylaxis, mood stabilisation and convulsions, in particular the treatment of convulsions due to epilepsy, also treatment of depression or psychomotor retardation in subjects prone to seizures. Dopamine uptake inhibitors are employed, especially benzhydryloxy-ethyl piperazine derivatives, including GBR12909, GBR12935, GBR13069, GBR13098, GBR13119 and pharmaceutically acceptable salts thereof.
PCT/GB2005/000119 2004-01-14 2005-01-14 Dopamine uptake inhibitors for the treatment of neurological disease WO2005067931A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0400802A GB0400802D0 (en) 2004-01-14 2004-01-14 Compounds for the treatment of disease
GB0400802.5 2004-01-14

Publications (2)

Publication Number Publication Date
WO2005067931A2 WO2005067931A2 (en) 2005-07-28
WO2005067931A3 true WO2005067931A3 (en) 2005-09-15

Family

ID=31726178

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2005/000118 WO2005067930A2 (en) 2004-01-14 2005-01-14 Serotonin receptor antagonists for the treatment of neurological disease
PCT/GB2005/000119 WO2005067931A2 (en) 2004-01-14 2005-01-14 Dopamine uptake inhibitors for the treatment of neurological disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/000118 WO2005067930A2 (en) 2004-01-14 2005-01-14 Serotonin receptor antagonists for the treatment of neurological disease

Country Status (2)

Country Link
GB (1) GB0400802D0 (en)
WO (2) WO2005067930A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007065713A2 (en) * 2005-12-08 2007-06-14 Axxonis Pharma Gmbh Use of 8-alpha-ergolines for the treatment of traumatic brain disorders
US20120028992A1 (en) * 2010-08-02 2012-02-02 Brown Arthur M Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013361340A1 (en) * 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
WO2015119938A1 (en) * 2014-02-05 2015-08-13 Chanrx Corporation Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia, and/or maintaining normal sinus rhythm in mammals
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009955A (en) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 Treatment of depression and various other disorders with psilocybin
GB201911024D0 (en) * 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSEN P H: "THE DOPAMINE UPTAKE INHIBITOR GBR-12909 SELECTIVITY AND MOLECULAR MECHANISM OF ACTION", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 166, no. 3, 1989, pages 493 - 504, XP002327585, ISSN: 0014-2999 *
CLINCKERS R ET AL: "Anticonvulsant action of GBR-12909 and citalopram against acute experimentally induced limbic seizures", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 47, no. 7, December 2004 (2004-12-01), pages 1053 - 1061, XP004650289, ISSN: 0028-3908 *
CLINCKERS RALPH ET AL: "Importance of hippocampal dopamine and serotonin in controlling hippocampal excitability.", EPILEPSIA, vol. 44, no. Supplement 9, 2003, & ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY; BOSTON, MA, USA; DECEMBER 05-10, 2003, pages 259 - 260, XP002327584, ISSN: 0013-9580 *
HANSARD MATTHEW J ET AL: "Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridi ne-treated primates.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. DEC 2002, vol. 303, no. 3, December 2002 (2002-12-01), pages 952 - 958, XP002327586, ISSN: 0022-3565 *
SOGAARD U ET AL: "A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects.", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. OCT 1990, vol. 5, no. 4, October 1990 (1990-10-01), pages 237 - 251, XP009047476, ISSN: 0268-1315 *

Also Published As

Publication number Publication date
WO2005067931A2 (en) 2005-07-28
WO2005067930A3 (en) 2006-02-23
GB0400802D0 (en) 2004-02-18
WO2005067930A2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
WO2005067931A3 (en) Dopamine uptake inhibitors for the treatment of neurological disease
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
MX2009010407A (en) Fluorinated derivatives of deferiprone.
BRPI0517227A (en) 1 - {[alpha-isobutanoyloxyethoxy) carbonyl] amino methyl} -1-cyclic acetic acid extended release oral dosage form, and method of treating a disease or condition
SI2324008T1 (en) 3,4-diarylpyrazoles as protein kinase inhibitors
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
HK1151736A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
MX337100B (en) Alkoxy compounds for disease treatment.
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2006033006A3 (en) Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
HK1196123A1 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
WO2006098761A3 (en) Hsp90 inhibitors, methods of making and uses therefor
WO2007035620A3 (en) Carbazole derivatives
ZA200907313B (en) Styrenyl derivative compounds for treating ophthalmic diseases and disorders
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase